[{"orgOrder":0,"company":"University of Illinois, Chicago","sponsor":"Theravance Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Telavancin","moa":"Cell outer membrane","graph1":"Undisclosed","graph2":"Phase I","graph3":"University of Illinois, Chicago","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Illinois, Chicago \/ Theravance Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"University of Illinois, Chicago \/ Theravance Biopharma"},{"orgOrder":0,"company":"University of Michigan","sponsor":"Theravance Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Telavancin","moa":"Cell outer membrane","graph1":"Nephrology","graph2":"Phase IV","graph3":"University of Michigan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan \/ Theravance Biopharma","highestDevelopmentStatusID":"11","companyTruncated":"University of Michigan \/ Theravance Biopharma"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Theravance Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Telavancin","moa":"Cell outer membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Theravance Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Theravance Biopharma"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Telavancin","moa":"Cell outer membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Telavancin","moa":"Cell outer membrane","graph1":"Nephrology","graph2":"Phase I","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Telavancin","moa":"Cell outer membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aaron Cook","sponsor":"Cumberland Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Telavancin","moa":"Cell outer membrane","graph1":"Neurology","graph2":"Phase IV","graph3":"Aaron Cook","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aaron Cook \/ Cumberland Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Aaron Cook \/ Cumberland Pharmaceuticals"},{"orgOrder":0,"company":"Joseph Kuti","sponsor":"Cumberland Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Telavancin","moa":"Cell outer membrane","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Joseph Kuti","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Joseph Kuti \/ Cumberland Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Joseph Kuti \/ Cumberland Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals for Telavancin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Aaron Cook

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Aaron Cook

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Telavancin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Subarachnoid Hemorrhage.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 07, 2023

                          Lead Product(s) : Telavancin

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase IV

                          Sponsor : Cumberland Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Joseph Kuti

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Joseph Kuti

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Telavancin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cystic Fibrosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 01, 2017

                          Lead Product(s) : Telavancin

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase IV

                          Sponsor : Cumberland Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          University of Illinois, Chicago

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          University of Illinois, Chicago

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Telavancin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 28, 2016

                          Lead Product(s) : Telavancin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Theravance Biopharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          University of Michigan

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          University of Michigan

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Telavancin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Failure, Chronic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 18, 2015

                          Lead Product(s) : Telavancin

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase IV

                          Sponsor : Theravance Biopharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Telavancin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Bacteremia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 04, 2014

                          Lead Product(s) : Telavancin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Telavancin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Gram-Positive Bacterial Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 17, 2013

                          Lead Product(s) : Telavancin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          MD Anderson Cancer Center

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          MD Anderson Cancer Center

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Telavancin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 24, 2011

                          Lead Product(s) : Telavancin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Theravance Biopharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Telavancin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Kidney Diseases.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 11, 2010

                          Lead Product(s) : Telavancin

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank